@EmmaStone 1 week ago
AbbVie’s neuroscience business is becoming a quiet growth driver
AbbVie’s neuroscience business is becoming a quiet growth driver
is getting more attention as its neuroscience portfolio becomes an increasingly important part of the business.
With demand for treatments in areas like migraine and neurological disorders growing, neuroscience could become a bigger contributor to long-term growth.
Do you think neuroscience pipeline is being overlooked by investors?
There are no comments here, be the first to comment
